TrialsgrambetaRCTs are beautiful

CARAVAGGIO

2020

Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer

In 1,170 patients with cancer-associated venous thromboembolism, apixaban was non-inferior to dalteparin for recurrent VTE, without excess major bleeding.

Result

Efficacy: Recurrent venous thromboembolismHR 0.63

Below 1 favours apixaban, above 1 favours dalteparin.

Event rates
Absolute difference
2.3 points

The absolute difference is derived from the event rates.

Also reported: No excess gastrointestinal bleeding.

Original publication
Subtopic
Venous thromboembolism
Design
Open-label, non-inferiority RCT
Relevance
Important: one of several pillars.
Source
Agnelli G, et al. N Engl J Med. 2020;382(17):1599-1607.doi 10.1056/NEJMoa1915103

Discussion & critique

Unlike edoxaban (Hokusai-Cancer), apixaban showed no GI-bleeding signal; it is a preferred oral option in cancer-associated VTE, including gastrointestinal tumours.

Discussed in podcasts